Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition

Steven F. Grieco, Yuyan Cheng, Hagit Eldar-Finkelman, Richard S Jope, Eleonore Beurel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

An antidepressant dose of the rapidly-acting ketamine inhibits glycogen synthase kinase-3 (GSK3) in mouse hippocampus, and this inhibition is required for the antidepressant effect of ketamine in learned helplessness depression-like behavior. Here we report that treatment with an antidepressant dose of ketamine (10 mg/kg) increased expression of insulin-like growth factor 2 (IGF2) in mouse hippocampus, an effect that required ketamine-induced inhibition of GSK3. Ketamine also inhibited hippocampal GSK3 and increased expression of hippocampal IGF2 in mice when administered after the induction of learned helplessness. Treatment with the specific GSK3 inhibitor L803-mts was sufficient to up-regulate hippocampal IGF2 expression. Administration of IGF2 siRNA reduced ketamine's antidepressant effect in the learned helplessness paradigm. Mice subjected to the learned helplessness paradigm were separated into two groups, those that were resilient (non-depressed) and those that were susceptible (depressed). Non-depressed resilient mice displayed higher expression of IGF2 than susceptible mice. These results indicate that IGF2 contributes to ketamine's antidepressant effect and that IGF2 may confer resilience to depression-like behavior.

Original languageEnglish (US)
Pages (from-to)49-54
Number of pages6
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume72
DOIs
StatePublished - Jan 4 2017

Fingerprint

Glycogen Synthase Kinase 3
Ketamine
Somatomedins
Learned Helplessness
Up-Regulation
Antidepressive Agents
Hippocampus
Depression
Inhibition (Psychology)
Small Interfering RNA

Keywords

  • Depression
  • Glycogen synthase kinase-3
  • Hippocampus
  • Insulin-like growth factor 2
  • Ketamine
  • Learned helplessness

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. / Grieco, Steven F.; Cheng, Yuyan; Eldar-Finkelman, Hagit; Jope, Richard S; Beurel, Eleonore.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 72, 04.01.2017, p. 49-54.

Research output: Contribution to journalArticle

@article{1c9f6a168a134ea49316df36dfcbdfb4,
title = "Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition",
abstract = "An antidepressant dose of the rapidly-acting ketamine inhibits glycogen synthase kinase-3 (GSK3) in mouse hippocampus, and this inhibition is required for the antidepressant effect of ketamine in learned helplessness depression-like behavior. Here we report that treatment with an antidepressant dose of ketamine (10 mg/kg) increased expression of insulin-like growth factor 2 (IGF2) in mouse hippocampus, an effect that required ketamine-induced inhibition of GSK3. Ketamine also inhibited hippocampal GSK3 and increased expression of hippocampal IGF2 in mice when administered after the induction of learned helplessness. Treatment with the specific GSK3 inhibitor L803-mts was sufficient to up-regulate hippocampal IGF2 expression. Administration of IGF2 siRNA reduced ketamine's antidepressant effect in the learned helplessness paradigm. Mice subjected to the learned helplessness paradigm were separated into two groups, those that were resilient (non-depressed) and those that were susceptible (depressed). Non-depressed resilient mice displayed higher expression of IGF2 than susceptible mice. These results indicate that IGF2 contributes to ketamine's antidepressant effect and that IGF2 may confer resilience to depression-like behavior.",
keywords = "Depression, Glycogen synthase kinase-3, Hippocampus, Insulin-like growth factor 2, Ketamine, Learned helplessness",
author = "Grieco, {Steven F.} and Yuyan Cheng and Hagit Eldar-Finkelman and Jope, {Richard S} and Eleonore Beurel",
year = "2017",
month = "1",
day = "4",
doi = "10.1016/j.pnpbp.2016.08.008",
language = "English (US)",
volume = "72",
pages = "49--54",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition

AU - Grieco, Steven F.

AU - Cheng, Yuyan

AU - Eldar-Finkelman, Hagit

AU - Jope, Richard S

AU - Beurel, Eleonore

PY - 2017/1/4

Y1 - 2017/1/4

N2 - An antidepressant dose of the rapidly-acting ketamine inhibits glycogen synthase kinase-3 (GSK3) in mouse hippocampus, and this inhibition is required for the antidepressant effect of ketamine in learned helplessness depression-like behavior. Here we report that treatment with an antidepressant dose of ketamine (10 mg/kg) increased expression of insulin-like growth factor 2 (IGF2) in mouse hippocampus, an effect that required ketamine-induced inhibition of GSK3. Ketamine also inhibited hippocampal GSK3 and increased expression of hippocampal IGF2 in mice when administered after the induction of learned helplessness. Treatment with the specific GSK3 inhibitor L803-mts was sufficient to up-regulate hippocampal IGF2 expression. Administration of IGF2 siRNA reduced ketamine's antidepressant effect in the learned helplessness paradigm. Mice subjected to the learned helplessness paradigm were separated into two groups, those that were resilient (non-depressed) and those that were susceptible (depressed). Non-depressed resilient mice displayed higher expression of IGF2 than susceptible mice. These results indicate that IGF2 contributes to ketamine's antidepressant effect and that IGF2 may confer resilience to depression-like behavior.

AB - An antidepressant dose of the rapidly-acting ketamine inhibits glycogen synthase kinase-3 (GSK3) in mouse hippocampus, and this inhibition is required for the antidepressant effect of ketamine in learned helplessness depression-like behavior. Here we report that treatment with an antidepressant dose of ketamine (10 mg/kg) increased expression of insulin-like growth factor 2 (IGF2) in mouse hippocampus, an effect that required ketamine-induced inhibition of GSK3. Ketamine also inhibited hippocampal GSK3 and increased expression of hippocampal IGF2 in mice when administered after the induction of learned helplessness. Treatment with the specific GSK3 inhibitor L803-mts was sufficient to up-regulate hippocampal IGF2 expression. Administration of IGF2 siRNA reduced ketamine's antidepressant effect in the learned helplessness paradigm. Mice subjected to the learned helplessness paradigm were separated into two groups, those that were resilient (non-depressed) and those that were susceptible (depressed). Non-depressed resilient mice displayed higher expression of IGF2 than susceptible mice. These results indicate that IGF2 contributes to ketamine's antidepressant effect and that IGF2 may confer resilience to depression-like behavior.

KW - Depression

KW - Glycogen synthase kinase-3

KW - Hippocampus

KW - Insulin-like growth factor 2

KW - Ketamine

KW - Learned helplessness

UR - http://www.scopus.com/inward/record.url?scp=84983801468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983801468&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2016.08.008

DO - 10.1016/j.pnpbp.2016.08.008

M3 - Article

VL - 72

SP - 49

EP - 54

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -